Arca
Skip to content
Tools
Tools

MAPK1, MAPK3: Mitogen-activated protein kinase; ERK1/ERK2

Family in Homo sapiens that 3 drugs act on.

  • Drugs that act on it: 3
  • Approved: 0
  • In phases 1 to 3: 3
  • Sponsors: 1

Who is on it, and how far along

Every drug ChEMBL records acting on MAPK1, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 3

Approved0

    Phase 30

      Phase 21

      • Temuterkib

      Phase 12

      • ASN007
      • KO-947

      The landscape

      Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: Mitogen-activated protein kinase; ERK1/ERK2 inhibitor.
      TemuterkibPhase 2—Small moleculeInhibitor0
      ASN007Phase 1—Small moleculeInhibitor0
      KO-947Phase 1Kura OncologySmall moleculeInhibitor0

      Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL1907606, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-22. ChEMBL and Open Targets

      Esc

      Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

      Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.